BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma W, Zhao F, Yu X, Guan S, Suo H, Tao Z, Qiu Y, Wu Y, Cao Y, Jin F. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. J Transl Med 2020;18:442. [PMID: 33225954 DOI: 10.1186/s12967-020-02522-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Han T, Wang X, Wang Y, Chen X, Chen W, Yang Q. Identification of prognostic immune-related lncRNA signature predicting the overall survival for colorectal cancer. Sci Rep 2023;13:1333. [PMID: 36693898 DOI: 10.1038/s41598-023-28305-9] [Reference Citation Analysis]
2 Damane BP, Mkhize-kwitshana ZL, Kgokolo MC, Luvhengo T, Dlamini Z. Applying Artificial Intelligence Prediction Tools for Advancing Precision Oncology in Immunotherapy: Future Perspectives in Personalized Care. Artificial Intelligence and Precision Oncology 2023. [DOI: 10.1007/978-3-031-21506-3_12] [Reference Citation Analysis]
3 Qiu P, Guo Q, Lin J, Pan K, Chen J, Ding M. An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer. Sci Rep 2022;12:22322. [PMID: 36566321 DOI: 10.1038/s41598-022-26894-5] [Reference Citation Analysis]
4 Guo Q, Qiu P, Pan K, Lin J. Comprehensive analysis of cuproptosis-related long non-coding RNA signature and personalized therapeutic strategy of breast cancer patients. Front Oncol 2022;12:1081089. [PMID: 36620596 DOI: 10.3389/fonc.2022.1081089] [Reference Citation Analysis]
5 Chen J, Li X, Yan S, Li J, Zhou Y, Wu M, Ding J, Yang J, Yuan Y, Zhu Y, Wu W. An autophagy-related long non-coding RNA prognostic model and related immune research for female breast cancer. Front Oncol 2022;12:929240. [PMID: 36591508 DOI: 10.3389/fonc.2022.929240] [Reference Citation Analysis]
6 Liu B, Zhu N, Huo H, Long J, Ji X, Li J, Zhuang X, Wang H, Li L, Chen Y, Yang W, Zhao S. A 5-Pathway Signature Predicts Prognosis Based on Immune-Derived lncRNAs in Patients with Breast Cancer. J Oncol 2022;2022:2906049. [PMID: 36545126 DOI: 10.1155/2022/2906049] [Reference Citation Analysis]
7 Li G, Xu S, Yang S, Wu C, Zhang L, Wang H. An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma. Front Genet 2022;13:1029576. [PMID: 36568382 DOI: 10.3389/fgene.2022.1029576] [Reference Citation Analysis]
8 Wang B, Chen H, Yang R, Xing L, Chen C, Chen J. LncRNA RP11-551L14.4 suppresses breast cancer development by inhibiting the expression of miR-4472. PeerJ 2022;10:e14482. [PMID: 36523479 DOI: 10.7717/peerj.14482] [Reference Citation Analysis]
9 Zhang H, Zhang N, Wu W, Zhou R, Li S, Wang Z, Dai Z, Zhang L, Liu Z, Zhang J, Luo P, Liu Z, Cheng Q. Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma. Brief Bioinform 2022;23:bbac386. [PMID: 36136350 DOI: 10.1093/bib/bbac386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Zheng J, Cai X, Zhang Y, Wang H, Liu L, Tang F, Liu L, Sun Y. A comprehensive pan-cancer analysis of necroptosis molecules in four gynecologic cancers. BMC Cancer 2022;22:1160. [DOI: 10.1186/s12885-022-10166-6] [Reference Citation Analysis]
11 Gao S, Wu X, Lou X, Cui W. Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer. Front Genet 2022;13:960567. [DOI: 10.3389/fgene.2022.960567] [Reference Citation Analysis]
12 Wang Z, Yao J, Dong T, Niu X, Wang F. Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma. Journal of Immunology Research 2022;2022:1-40. [DOI: 10.1155/2022/2756611] [Reference Citation Analysis]
13 Li H, Liu Z, Chen Y, Zhang X, Wu N, Wang J. Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer. Front Oncol 2022;12:999654. [DOI: 10.3389/fonc.2022.999654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sherif S, Mall R, Almeer H, Naik A, Al Homaid A, Thomas R, Roelands J, Narayanan S, Mohamed MG, Bedri S, Al-Bader SB, Junejo K, Bedognetti D, Hendrickx W, Decock J. Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting. J Transl Med 2022;20:442. [PMID: 36180904 DOI: 10.1186/s12967-022-03654-7] [Reference Citation Analysis]
15 Zhang Q, Huang Y, Xia Y, Liu Y, Gan J. Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma. Clin Exp Med. [DOI: 10.1007/s10238-022-00892-3] [Reference Citation Analysis]
16 Lv W, Tan Y, Zhou X, Zhang Q, Zhang J, Wu Y. Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer. Front Immunol 2022;13:989928. [DOI: 10.3389/fimmu.2022.989928] [Reference Citation Analysis]
17 Ding Y, Li X, Li J, Liqun Zhu. COVID-19–associated lncRNAs as predictors of survival in uterine corpus endometrial carcinoma: A prognostic model. Front Genet 2022;13:986453. [DOI: 10.3389/fgene.2022.986453] [Reference Citation Analysis]
18 Xu J, Qin S, Yi Y, Gao H, Liu X, Ma F, Guan M. Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq. IJMS 2022;23:9936. [DOI: 10.3390/ijms23179936] [Reference Citation Analysis]
19 Xin Y, Zhang J, Jiang Q, Qiu J. Construction of prognostic signature of patients with oral squamous cell carcinoma based on pyroptosis-related long non-coding RNAs. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.935765] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Bjørklund SS, Aure MR, Häkkinen J, Vallon-Christersson J, Kumar S, Evensen KB, Fleischer T, Tost J, Sahlberg KK, Mathelier A, Bhanot G, Ganesan S, Tekpli X, Kristensen VN; OSBREAC. Subtype and cell type specific expression of lncRNAs provide insight into breast cancer. Commun Biol 2022;5:834. [PMID: 35982125 DOI: 10.1038/s42003-022-03559-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhu J, Lyu A, Wang Z, Chan W, Qin T, Miu K, Yao H, Wang F. Machine Learning-Devised Immune-Related lncRNA Signature Panel Predicts the Prognosis and Immune Landscape in Breast Cancer Novel IRLP Signature in BRCA. Journal of Immunology Research 2022;2022:1-16. [DOI: 10.1155/2022/3704798] [Reference Citation Analysis]
22 Zhang X, Yang Q, Ashfaq UA. An Immune-Related lncRNA Pairing Model for Predicting the Prognosis and Immune-Infiltrating Cell Condition in Human Ovarian Cancer. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/3168408] [Reference Citation Analysis]
23 Xu Y, Chen Y, Niu Z, Yang Z, Xing J, Yin X, Guo L, Zhang Q, Yang Y, Han Y. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.860806] [Reference Citation Analysis]
24 Hong Y, Que Y, Hu Y, Shi BY, Zhu J, Wang J, Huang JT, Sun FF, Zhang L, Zhou XK, Lu SY, Zhang YZ. Immune-Related LncRNAs as Prognostic Factors for Pediatric Rhabdoid Tumor of the Kidney. Dis Markers 2022;2022:4752184. [PMID: 35756490 DOI: 10.1155/2022/4752184] [Reference Citation Analysis]
25 Zhang LP, Lin H, Wang AJ. Development and validation of a nomogram to predict survival for advanced male breast cancer. Andrologia 2022;:e14479. [PMID: 35618959 DOI: 10.1111/and.14479] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Ning S, Wu J, Pan Y, Qiao K, Li L, Huang Q. Identification of CD4+ Conventional T Cells-Related lncRNA Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Breast Cancer. Front Immunol 2022;13:880769. [PMID: 35603183 DOI: 10.3389/fimmu.2022.880769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Ye P, Feng L, Shi S, Dong C. The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer. Cancers (Basel) 2022;14:2101. [PMID: 35565231 DOI: 10.3390/cancers14092101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Olmedo-suárez MÁ, Ramírez-díaz I, Pérez-gonzález A, Molina-herrera A, Coral-garcía MÁ, Lobato S, Sarvari P, Barreto G, Rubio K. Epigenetic Regulation in Exposome-Induced Tumorigenesis: Emerging Roles of ncRNAs. Biomolecules 2022;12:513. [DOI: 10.3390/biom12040513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Bao T, Wang Z, Xu J. Immune-Related lncRNAs Pairs to Construct a Novel Signature for Predicting Prognosis in Gastric Cancer. Front Surg 2022;9:807778. [DOI: 10.3389/fsurg.2022.807778] [Reference Citation Analysis]
30 Li R, Li J, Liu T, Huo C, Yao J, Ji X, Qu Y. Prognostic Value of Genomic Instability of m6A-Related lncRNAs in Lung Adenocarcinoma. Front Cell Dev Biol 2022;10:707405. [DOI: 10.3389/fcell.2022.707405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jiang Z, Li J, Feng W, Sun Y, Bu J, Wang F. A Ferroptosis-Related lncRNA Model to Enhance the Predicted Value of Cervical Cancer. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/6080049] [Reference Citation Analysis]
32 Melixetian M, Pelicci PG, Lanfrancone L. Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process. Cells 2022;11:577. [PMID: 35159386 DOI: 10.3390/cells11030577] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
33 Sun S, Zhang G, Zhang L. A Novel Ferroptosis-Related lncRNA Prognostic Model and Immune Infiltration Features in Skin Cutaneous Melanoma. Front Cell Dev Biol 2022;9:790047. [DOI: 10.3389/fcell.2021.790047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zheng J, Guo J, Wang Y, Zheng Y, Zhang K, Tong J. Bioinformatic Analyses of the Ferroptosis-Related lncRNAs Signature for Ovarian Cancer. Front Mol Biosci 2022;8:735871. [DOI: 10.3389/fmolb.2021.735871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Peng Y, Wang H, Huang Q, Wu J, Zhang M. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer. J Ovarian Res 2022;15:8. [PMID: 35031063 DOI: 10.1186/s13048-021-00930-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
36 Gu P, Zhang L, Wang R, Ding W, Wang W, Liu Y, Wang W, Li Z, Yan B, Sun X. Development and Validation of a Novel Hypoxia-Related Long Noncoding RNA Model With Regard to Prognosis and Immune Features in Breast Cancer. Front Cell Dev Biol 2021;9:796729. [PMID: 34977036 DOI: 10.3389/fcell.2021.796729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
37 Sun Q, Li Y, Yang X, Wu X, Liu Z, Mou Y, Song X. Identification and Validation of 17-lncRNA Related to Regulatory T Cell Heterogeneity as a Prognostic Signature for Head and Neck Squamous Cell Carcinoma. Front Immunol 2021;12:782216. [PMID: 34880875 DOI: 10.3389/fimmu.2021.782216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Xu M, Zhang R, Qiu J. A four immune-related long noncoding RNAs signature as predictors for cervical cancer. Hum Cell 2021. [PMID: 34846702 DOI: 10.1007/s13577-021-00654-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Izadi M, Ali TA, Pourkarimi E. Over Fifty Years of Life, Death, and Cannibalism: A Historical Recollection of Apoptosis and Autophagy. Int J Mol Sci 2021;22:12466. [PMID: 34830349 DOI: 10.3390/ijms222212466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
40 Li S, Sun X, Li J, Zheng A, Cao Y, Guo Y, Jin F. A Novel Prognostic Signature of Immune-Related Long Noncoding RNA Pairs for Tumor-Infiltrating Immune Cells and Drug Susceptibility in Breast Cancer. DNA Cell Biol 2021. [PMID: 34762509 DOI: 10.1089/dna.2021.0489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Lv W, Wang Y, Zhao C, Tan Y, Xiong M, Yi Y, He X, Ren Y, Wu Y, Zhang Q. Identification and Validation of m6A-Related lncRNA Signature as Potential Predictive Biomarkers in Breast Cancer. Front Oncol 2021;11:745719. [PMID: 34722303 DOI: 10.3389/fonc.2021.745719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
42 Zhang J, Shan B, Lin L, Dong J, Sun Q, Zhou Q, Chen J, Han X. Dissecting the Role of N6-Methylandenosine-Related Long Non-coding RNAs Signature in Prognosis and Immune Microenvironment of Breast Cancer. Front Cell Dev Biol 2021;9:711859. [PMID: 34692676 DOI: 10.3389/fcell.2021.711859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Gao Z, Wu D, Zheng W, Zhu T, Sun T, Yuan L, Fei F, Fu P. Prognostic value of immune-related lncRNA pairs in patients with bladder cancer. World J Surg Oncol 2021;19:304. [PMID: 34663340 DOI: 10.1186/s12957-021-02419-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Chen ZA, Tian H, Yao DM, Zhang Y, Feng ZJ, Yang CJ. Identification of a Ferroptosis-Related Signature Model Including mRNAs and lncRNAs for Predicting Prognosis and Immune Activity in Hepatocellular Carcinoma. Front Oncol 2021;11:738477. [PMID: 34568075 DOI: 10.3389/fonc.2021.738477] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
45 Chen H, Shen W, Ni S, Sang M, Wu S, Mu Y, Liu K, Li N, Zhu L, Xu G. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD. Aging (Albany NY) 2021;13:20684-97. [PMID: 34438369 DOI: 10.18632/aging.203455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
46 Dastmalchi N, Safaralizadeh R, Latifi-Navid S, Banan Khojasteh SM, Mahmud Hussen B, Teimourian S. An updated review of the role of lncRNAs and their contribution in various molecular subtypes of breast cancer. Expert Rev Mol Diagn 2021;:1-12. [PMID: 34334086 DOI: 10.1080/14737159.2021.1962707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Li YX, Wang SM, Li CQ. Four-lncRNA immune prognostic signature for triple-negative breast cancer Running title: Immune lncRNAs predict prognosis of TNBC. Math Biosci Eng 2021;18:3939-56. [PMID: 34198419 DOI: 10.3934/mbe.2021197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wang Y, Liu J, Ren F, Chu Y, Cui B. Identification and Validation of a Four-Long Non-coding RNA Signature Associated With Immune Infiltration and Prognosis in Colon Cancer. Front Genet 2021;12:671128. [PMID: 34290738 DOI: 10.3389/fgene.2021.671128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
49 Mathias C, Muzzi JCD, Antunes BB, Gradia DF, Castro MAA, Carvalho de Oliveira J. Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes. Front Oncol 2021;11:692170. [PMID: 34136413 DOI: 10.3389/fonc.2021.692170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
50 Hassani B, Taheri M, Asgari Y, Zekri A, Sattari A, Ghafouri-Fard S, Pouresmaeili F. Expression Analysis of Long Non-Coding RNAs Related With FOXM1, GATA3, FOXA1 and ESR1 in Breast Tissues. Front Oncol 2021;11:671418. [PMID: 34094972 DOI: 10.3389/fonc.2021.671418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Lv Y, Lv X, Yang H, Qi X, Wang X, Li C, Shang X, Guo H, Zhang J, Zhang Y. LncRNA SNHG6/miR-125b-5p/BMPR1B Axis: A New Therapeutic Target for Triple-Negative Breast Cancer. Front Oncol 2021;11:678474. [PMID: 34026654 DOI: 10.3389/fonc.2021.678474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Guo JH, Yin SS, Liu H, Liu F, Gao FH. Tumor microenvironment immune-related lncRNA signature for patients with melanoma. Ann Transl Med 2021;9:857. [PMID: 34164491 DOI: 10.21037/atm-21-1794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]